Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results

SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report fourth quarter and full year 2023 financial results after the U.S. financial markets close on Thursday, March 7,…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks